)
10X Genomics (TXG) investor relations material
10X Genomics Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Achieved $150.8 million in Q1 2026 revenue, up 9% year-over-year excluding prior year settlement/license revenue.
Launched Atera, a major new spatial biology platform, with strong early demand, pre-orders, and shipments expected in H2 2026.
Double-digit growth in both single-cell and spatial consumables, driven by Flex Apex and Xenium.
Maintained disciplined cost management, with operating expenses down 15–20% year-over-year excluding one-time items.
Announced partnerships and initiatives in AI-driven biology and translational research, including Bioptimus and STELA.
Financial highlights
Q1 2026 revenue: $150.8 million, up 9% year-over-year excluding non-recurring settlement/license revenue.
Consumables revenue up 13%; single-cell consumables up 6%, spatial consumables up 31%.
Instrument revenue declined 24% year-over-year; Chromium instruments down 12%, spatial instruments down 32%.
Gross margin improved to 70% from 68% in Q1 2025, driven by lower warranty and inventory costs.
Ended quarter with $540 million in cash and equivalents, up $113 million year-over-year.
Outlook and guidance
Full-year 2026 revenue expected at $600–$625 million, representing 0–4% growth over 2025 excluding settlement/license revenue.
Double-digit growth anticipated in single-cell and spatial consumables for the year.
Q2 and Q3 revenue expected to decline sequentially due to customers delaying spatial purchases ahead of Atera launch.
Atera shipments to begin contributing in Q4/H2, with initial production capacity limited.
Gross margin for 2026 expected in the mid-60s%, with some pressure from Atera launch in Q4.
- 2026 proxy covers director elections, auditor ratification, and executive pay, with strong governance focus.TXG
Proxy filing24 Apr 2026 - Director elections, auditor ratification, and executive pay are up for vote at the annual meeting.TXG
Proxy filing24 Apr 2026 - Atera delivers high-throughput, single-cell spatial transcriptomics with unmatched flexibility.TXG
Corporate presentation19 Apr 2026 - Consumables growth and cost discipline drove revenue above guidance as losses narrowed.TXG
Q4 202513 Apr 2026 - Innovation and strong cash flow drive growth amid macro challenges and evolving customer needs.TXG
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Spatial consumables growth drove 4% revenue gain; 2024 guidance lowered amid macro headwinds.TXG
Q2 20242 Feb 2026 - Strong product launches and sales reorganization position the company for scalable growth.TXG
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 2024 revenue fell 1%, with strong consumables growth and new launches amid market headwinds.TXG
Q3 202418 Jan 2026 - Despite a tough 2024, new products and restructuring set the stage for robust future growth.TXG
Wolfe Research Healthcare Conference 202413 Jan 2026
Next 10X Genomics earnings date
Next 10X Genomics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage